Your browser doesn't support javascript.
loading
Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience.
Grewal, Udhayvir S; Loeffler, Bradley T; Paschke, Alexander; Dillon, Joseph S; Chandrasekharan, Chandrikha.
Afiliación
  • Grewal US; Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
  • Loeffler BT; University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA.
  • Paschke A; University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA.
  • Dillon JS; Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
  • Chandrasekharan C; University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA.
J Gastrointest Cancer ; 55(3): 1165-1170, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38780680
ABSTRACT

INTRODUCTION:

The available data for the safety and efficacy of repeat peptide receptor radionuclide therapy (PRRT) are almost exclusively from European centers. We present an updated experience with repeat PRRT in a cohort of US patients with neuroendocrine tumors (NETs) at our NET center of excellence.

METHODS:

We used our single-center longitudinal NET registry to identify patients who had been previously treated with at least one dose of PRRT (PRRT 1, either 177Lu DOTATATE or 90Y DOTATOC) and following radiographic disease progression were re-treated with a second course of PRRT (PRRT 2). We reviewed patient, tumor and treatment characteristics, objective response rates, and toxicities after PRRT 1 and PRRT 2.

RESULTS:

A total of 11 patients were included in the analysis. 45.5% (5/11) of patients received 177Lu DOTATATE PRRT only, both for PRRT1 and PRRT 2, while 54.5% (6/11) of patients received 90Y DOTATOC PRRT for PRRT1. At first restaging scan after PRRT2 (3-6 months), 18.2% (2/11), 36.4% (4/11), and 27.3% (3/11) of patients had PR, SD, and PD, respectively; 2/11 patients (18.2%) died before the first restaging scan. Therefore, 5/11 (45.5%) patients were noted to have disease progression. Median PFS for PRRT1 was 25.4 months and median PFS for PRRT2 was 13.1 months (p = 0.0001). We did not find a statistically significant difference between the occurrence of short and long-term hematological toxicities as well as renal toxicity after PRRT1 and PRRT2.

CONCLUSION:

We show that repeat PRRT may benefit select patients and have an acceptable safety profile. In our cohort, PFS was significantly lower after PRRT2 as compared to PRRT1.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Octreótido / Tumores Neuroendocrinos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Gastrointest Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Octreótido / Tumores Neuroendocrinos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Gastrointest Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos